About Us
We are transforming precision medicine
Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology.
Our proprietary whole genome analysis platform allows us to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations.
Our Team
Leadership at Variantyx
Our talented, interdisciplinary team of professionals has broad expertise in technology innovation, clinical genomics, bioinformatics, software engineering, information technology, and operations. We enable our customers to provide advanced diagnostics, offer precision treatment support, or gain insights to improve drug development.
Executive Team
Haim Neerman
CEO
Haim Neerman
Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.
Edward Sitar
CFO
Edward Sitar
Ed oversees global financial performance at Variantyx. Prior to his work at Variantyx, Ed served as the Chief Financial Officer of 9Meters Biopharma (Nasdaq:NMTR), a clinical stage company developing therapeutic approaches that treat people with rare and debilitating conditions by leveraging the biology of the gut. Ed is an experienced financial executive with an extensive healthcare background. He has led both public and private companies, raising substantial capital and improving operations. He holds a B.S. in accounting from the University of Scranton and is licensed as a Certified Public Accountant in New Jersey.
Yaron Rachmany
COO
Yaron Rachmany
Yaron Rachmany oversees Operations, R&D, IT Systems and Security, Information Systems and Business Processes at Variantyx. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information Systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi (NASDAQ: MSCC), Intel (NASDAQ: INTC) and ECI Telecom. Yaron holds an M.Sc. and a B.Sc. in Industrial Engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.
Christine Stanley PhD, FACMG
Chief Director of Clinical Genomics
Christine Stanley PhD, FACMG
Chief Director of Clinical Genomics |
As Chief Director of Clinical Genomics at Variantyx, Christine is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory. Prior to joining Variantyx, Christine held positions as Head of Clinical Laboratory at WuXi NextCODE, Chief Director of Clinical Genomics at Courtagen Life Sciences and Genetics Director at Athena Diagnostics. Christine holds a Bachelor’s degree in Genetics from Texas A&M University and a PhD in Human Genetics from the Medical College of Virginia with fellowship training at Boston University in clinical molecular genetics. She is a diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.
Eyal Reinstein, MD, PhD, DABMGG
Chief Medical Officer
Eyal Reinstein, MD, PhD, DABMGG
Eyal serves as the Chief Medical Officer and joined Variantyx in December 2019 as a medical director reviewing, advising, and approving clinical cases. Eyal earned his PhD in biochemistry and MD in internal medicine, both from the Technion-Israel Institute of Technology. He completed his clinical genetics fellowship at the UCLA Medical Genetics Program. During his career, he has authored over 50 scientific papers delineating novel genetic disorders and phenotypes including heritable connective tissue disorders, cardiac and eye abnormalities, and intellectual disability syndromes. Prior to joining Variantyx, he served as a clinical geneticist in multiple academic medical centers, was the Director of the Department of Medical Genetics at Meir Medical Center in Israel, and an Associate Professor of Internal Medicine at Tel-Aviv University. From 2016-2021, he served as a member of both the Helsinki Committee of the Israel Ministry of Health and the Meir Medical Center. He is a diplomate of the American Board of Medical Genetics and Genomics.
Eric Olivares, PhD
Chief Scientific Officer
Eric Olivares, PhD
Eric serves as the Chief Scientific Officer at Variantyx and has over 15 years of experience in assay development and clinical lab operations. He previously spent a decade designing, building, and scaling Invitae’s clinical testing operations, which received over 1 million high complexity NGS tests per year when he departed. Prior to his work at Invitae, he was a Senior Staff Scientist at Pacific Biosciences where he improved sample prep kits and workflows, and a Senior Staff Scientist at Invitrogen where he developed cross-platform NGS sample prep kits. In 2007, Eric founded SEQanswers.com, a leading online resource for bench and bioinformatics scientists to share protocols and troubleshoot processes. He completed his BS in 1998 from the University of California, Davis and his PhD in 2003 from Stanford University. He enjoys playing guitar, exercising, and spending time with his family at their home in Maine.
Christopher Zerwas
VP of Sales
Christopher Zerwas
Chris serves as the VP of Sales. Chris’ primary focus is to drive revenue growth by leading a sales team to educate clinicians, and their supporting staff, about genomic testing capabilities and services at Variantyx. Chris brings 23 years of clinical genetic testing experience to Variantyx. Prior to Variantyx, Chris held senior sales management positions with PerkinElmer Genomics, GeneDx, and Athena Diagnostics. Chris holds a Bachelor’s degree in Marketing from Pacific University.
Tomer Jackman
VP Customer Support and Laboratory Services
Tomer Jackman
VP Customer Support and Laboratory Services |
As VP Customer Support and Lab Services, Tomer is responsible for delivering services to customers. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in the Pivotal/Greenplum division of EMC2 where he helped develop server clusters for “Massive Parallel Processing” databases. This followed a decade with EMC2 in several hardware engineering roles and work in R&D with HP/Indigo. Tomer holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.
Tom DeLuca
Chief Human Resources Officer
Tom DeLuca
Chief Human Resources Officer
Tom DeLuca serves as our Chief Human Resources Officer. Tom’s primary focus is to lead HR operations and oversee efforts surrounding organizational planning, DE&I, culture and engagement, recruitment, and learning as Variantyx grows. Prior to his time at Variantyx, Tom led the national sales and health plans organizations HR team for Quest Diagnostics, worked as VP of HR for Zelis Healthcare, and held senior HR positions with AIG, Cendant and Selective Insurance. Tom is a certified Myers-Briggs consultant and works to coach leaders on team effectiveness. Tom graduated from Kutztown University with a Bachelor’s degree in Business Administration.
Board of Directors
Haim Neerman
CEO
Haim Neerman
Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd. Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.
David Margulies, MD
Chairman
David Margulies, MD
Dr Margulies has been active in the healthtech industry since the early 1980s. He co-founded and led BRS Medical, later acquired by WB Saunders and, ultimately, Elsevier North Holland. While CIO at Boston Children’s Hospital, he led the design of software that was acquired by Cerner to be the basis of Cerner’s EMR, becoming EVP, Chief Scientist, and a BOD member at Cerner. He co-founded and was a Director of CareInsite (acquired by WebMD) and co-founded and was CEO and Chairman of Correlagen Diagnostics (acquired by LabCorp). Dr. Margulies was most recently VP of Strategy at Boston Children’s Hospital where he led development of the institution’s genomic medicine strategy and later co-founded and was Chairman of Q-State Biosciences. Over the years he has served on numerous public and private boards including D2 Hawkeye (acquired by Verisk), ObMedical (acquired by Philips), Circulation (acquired by Logisticare), Generation Health (acquired by CVS), Claritas Genomics (acquired by Q-State Biosciences), and Commonwealth Care Alliance. He currently serves as Director for Travera. Dr. Margulies received his BA from Amherst College and his MD from Harvard Medical School. He completed his clinical training and board certification in Internal Medicine at Columbia College of Physicians and Surgeons. Dr. Margulies recently retired from the faculties of Genetics and Bioinformatics at Harvard Medical School.
Hillel Bachrach, MBA
Board Member
Hillel Bachrach, MBA
Founder and Managing Partner at 20/20 Healthcare Partners, LLC
Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Variantyx, Hillel currently serves on the Board of Directors for Zixi and Velocamp. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd. which was sold to Pharmalogic in 2019. Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.
Zafrira Avnur, PhD
Board Member
Zafrira Avnur, PhD
Chief Scientific Officer and Partner at Quark Venture Inc
Dr Avnur is a Partner and Chief Scientific Officer at Quark Venture Inc, a global venture capital firm founded in 2016. She brings nearly 20 years of experience in pharmaceuticals and diagnostics research and development to her role, with significant scientific achievements including the advancement of three compounds (a PTHrP analog and two vitamin D analogs) from early exploratory discovery research to the clinic and being named Distinguished Scientist at Roche. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering, creating eleven startup companies. She also held the role of Global Head of Neglected Diseases, Roche Partnering, and started the “Finder” group for Biomarkers for all therapeutic areas at Roche where she acted as liaison between Pharma and Diagnostic Divisions and contributed to the Personalized Health Care initiative.
Gideon Argov, MBA
Board Member
Gideon Argov, MBA
Board Member
Managing Partner and Co-Founder at New Era
Gideon is a Managing Partner at New Era Capital Partners, the global investment firm he co-founded in 2017. He is also an Advisory Director of Berkshire Partners, an investment firm based in Boston. Prior to New Era, Gideon was President and CEO of Entegris, Managing Director of Parthenon Capital, a private equity partnership based in Boston, as well as President and CEO of Kollmorgen Corporation. He is a serial angel investor in Israeli technology companies and has served as the Chairman of Fundtech and Servotronix. Gideon is the founder of the Shlomo Argov Fellows program for leadership in the public sector at Reichman University (IDC Herzliya) in Israel and a trustee of the Beth Israel Deaconess Medical Center in Boston. He received his BA in economics from Harvard University and his MBA from the Stanford Graduate School of Business.
Hila Karah
Board Member
Hila Karah
Managing Partner at Pitango HealthTech
Hila is a Managing Partner of the HealthTech fund at Pitango, a global investment firm founded in 1993. She brings over 20 years of life science experience to her role, including time spent as a consultant advising on business strategy. Prior to Pitango, Hila was a Chief Investment Officer of Eurotrust Ltd., a Partner Senior Analyst at Perceptive Life Sciences Ltd., and VP Research at Oracle Partners Ltd. In addition to Variantyx, Hilla currently serves on the Board of Directors for Indaptus Therapeutics Ltd. (NASDAQ: INDP), Dario Health Corp. (NASDAQ: DRIO) and OncoHost Ltd. She also volunteers as an oncology case manager and serves as a professional manager at Mifrasim, a NOP social venture. Hila received a BA in molecular and cell biology from the University of California, Berkeley, and has studied as part of the UC Berkeley-UCSF joint medical program.
Investors
Variantyx is a privately-held, venture-backed company. We are supported by our international group of world-leading technology and healthcare investors.
